In response to the public debate in the US following the US Department of Treasury’s announcement of plans for Regulatory Reform Over-The-Counter (OTC) Derivatives, the ACT has made representations to certain US House and Senate committees reminding them that flexible OTC derivatives are used extensively by companies in their risk management activities and that standardised exchange traded derivatives could not fulfil the same essential purpose.
